GLYCOPYRROLATE 0.2 MG/ML VIAL

What it is

GLYCOPYRROLATE 0.2 MG/ML VIAL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as glycopyrrolate.

FDA gives its dosage form as “injection”, “injection, solution” and “solution” and its route as intramuscular; intravenous.

FDA lists 14 labelers (the companies named on the label) for its NDCs, among them Hikma Pharmaceuticals USA Inc., American Regent, Inc. and Sandoz Inc.

FDA lists it under 2 Established Pharmacologic Classes: Anticholinergic and Cholinergic Muscarinic Antagonist.

The NADAC file of 2026-10-14 prices it under 20 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1.51 for 1 mL (1 × $1.51425 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The 14 labelers

Other strengths, forms and brands

4 other products in the NADAC file share the FDA nonproprietary name glycopyrrolate with GLYCOPYRROLATE 0.2 MG/ML VIAL.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 20 NDCs’ NADAC prices is $1.51425 per ML filed.

Of the 12 other products in FDA’s Anticholinergic class priced per ML, 3 have a higher middle NADAC price and 9 a lower one. The one in the middle is TROPICAMIDE 1% EYE DROP, at $0.55153 per ML filed (eff. 2026-09-23).

Of the 6 other products in FDA’s Cholinergic Muscarinic Antagonist class priced per ML, 2 have a higher middle NADAC price and 4 a lower one. The one in the middle is GLYCOPYRROLATE 1 MG/5 ML ORAL SOLUTION, at $0.2019 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J1596, for 2026-10-01 to 2026-12-31, comes to $0.66 for 1 mL, or $0.66 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.066 per 0.1 MG.

14 of the product’s 20 NDCs have this Medicare figure; the other 6 do not, and the interactive card says why for each.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.